Immuni T is a CRO company, specialises in services for biotherapeutics and immunomodulators at very competitive rates. It has expertise in customized cell-based assays, flow cytometry and ELISA assays in bioanalysis in GLP/GCLP regulated laboratories. We have developed an ex vivo method for assessing the immunogenic potential of new biotherapeutics and biosimilars, an assay performed in freshly-collected PBMC from a number of donors. This assay, for example, could assist you in the selection of the less immunogenic lead from a set of variants or to compare the immunogenic profile of a biosimilar to that of its originator. It is a rapid and cost-effective means for the evaluation of the immunogenic potential of a molecule in a human system. We perform the development and validation of immunogenicity methods and of ligand-binding assays for PK analysis for pre-clinical and clinical programs. We developed functional customized cell-based assays such as cytotoxicity assays (e.g. ADCC, CDC, in PBMC, sub-cell compartments or whole blood) and other assays such as Treg or NK functional assays. Overall, Immuni T performs cell-based assays, human ex-vivo immunogenicity prediction/comparison assays for new biotherapeutics as well as immunogenicity tests for biotherapeutics in clinical development; ligand-binding assays for the quantification/detection of peptides, proteins or nucleic acids; immuno assays based on flow cytometry analysis for determination of cell function and molecules quantification; multiplex analysis on Luminex as well as customization, development and validation of assays for pre-clinical (in GLP-compliant environment) and clinical studies.